Summary
KLOW is a multi-peptide research formulation combining four distinct peptides — TB-500 (actin regulation), BPC-157 (angiogenesis modulation), GHK-Cu (copper-dependent remodeling), and KPV (an alpha-MSH C-terminal tripeptide studied in inflammation-pathway literature).
Overview
The KLOW complex extends the GLOW preparation by adding KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, which has its own published research history in anti-inflammatory model work. The four-peptide preparation is studied as a multi-pathway reference in repair- and inflammation-pathway modeling.
Research Background
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH and has been studied independently by Luger, Brzoska, and others since the 1990s for its anti-inflammatory pathway activity. Combined with the constituents of GLOW, KPV adds an inflammation-modulation axis to the preparation.
Mechanisms Studied
Mechanistic interest centers on the convergence of four distinct pathways: actin dynamics (TB-500), angiogenesis (BPC-157), copper-dependent remodeling (GHK-Cu), and melanocortin-fragment inflammation modulation (KPV). Each pathway has dedicated published mechanistic literature.
Published Research Summary
Published research on the individual components is extensive (see component guides for TB-500, BPC-157, GHK-Cu, plus the KPV literature led by Luger and Brzoska). Published research on the four-peptide combination specifically is limited and is framed as a rationale-driven multi-pathway preparation.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.